{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-OEY6F73Y/b62581ce-a491-41fe-99a3-35faeaf94a2d/PDF","dcterms:extent":"170 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-OEY6F73Y/8d664739-ae82-483e-bb73-3689f5d36793/TEXT","dcterms:extent":"53 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-OEY6F73Y","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2005","dc:creator":"Lešničar, Gorazd","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:74"},{"@xml:lang":"sl","#text":"str. 89-96"}],"dc:identifier":["ISSN:1318-0347","COBISSID_HOST:19200985","URN:URN:NBN:SI:doc-OEY6F73Y"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Drug Therapy"},{"@xml:lang":"sl","#text":"Hepatitis B"},{"@xml:lang":"sl","#text":"Hepatitis B E Antigens"},{"@xml:lang":"sl","#text":"Hepatitis B e, antigeni"},{"@xml:lang":"sl","#text":"Hepatitis, Chronic Active"},{"@xml:lang":"sl","#text":"Interferon-alfa"},{"@xml:lang":"sl","#text":"Interferon-Alpha"},{"@xml:lang":"sl","#text":"Jetra, ciroza"},{"@xml:lang":"sl","#text":"Lamivudin"},{"@xml:lang":"sl","#text":"Lamivudine"},{"@xml:lang":"sl","#text":"Liver Cirrhosis"},{"@xml:lang":"sl","#text":"Retrospective Studies"},{"@xml:lang":"sl","#text":"Retrospektivne študije"},{"@xml:lang":"sl","#text":"Treatment Outcome"},{"@xml:lang":"sl","#text":"Zdravljenje, izid"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Zdravljenje bolnikov s kroničnim hepatitisom B v Splošni bolnišnici Celje| Treatment of patients with chronic hepatitis B in General hospital Celje|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. A third of world's population has serological evidence of a past or current infection with hepatitis B virus and 350 million people have chronic infection. Chronic hepatitis B is associated with liver cirrhosis and hepatic cancer, i. e. the diseases that cause death in over a half million people yearly. It is estimated that there are approximately 20, 000 chronic hepatitis B virus carriers living in Slovenia. In our hospital, experimental use of interferon a for the treatment ofpatients with hepatitis B was started already in 1988, while the routine treatment with interferon a has been practised for ten years and with lamivudine for five years. Methods. A retrospective study carried out at the Department of Infectious Diseases and Febrile Conditions of the General Hospital Ce je was aimed at evaluating the effectiveness and safety of a protocol-based treatment in 35 patients (21 males and 14 females, mean age 41 years) with chronic hepatitis B (11 HBeAg positive) in the period 1994-2004 receiving inter feron a and/or lamivudine and since 2003 also pegylated interferon a and adefovir. (Abstract truncated at 2000 characters)"},{"@xml:lang":"sl","#text":"Izhodišča. Na svetu ima ena tretjina ljudi serološke znake pretekle ali sveže okužbe z virusom hepatitisa B in 350 milijonov ljudi je kronično okuženih. Kronični hepatitis B je razlog za jetrno cirozo in jetrnega raka, zaradi česarumre več kot pol milijona ljudi letno. Ocenjujejo, da v Sloveniji živi približno dvajset tisoč kroničnih nosilcev virusa hepatitisa B. Kronične bolnike s hepatitisom B smo pri nas pričeli poskusno zdraviti z interferonom aže leta 1988, rutinsko pa šele zadnjih deset let z interferonom a in pet let z lamivudinom. Metode. Na Oddelku za infekcijske bolezni in vročinska stanja Splošne bolnišnice v Celju smo retrospektivno raziskali učinkovitost in varnost sicer s protokolom načrtovanih zdravljenj pri 35 bolnikih (21 moških in 14 žensk) s kroničnim hepatitisom B (11 HBeAg pozitivnih), povprečno starih41 let. V obdobju 1994-2004 so bili zdravljeni z interferonom alfa in/ ali lamivudinom, po l. 2003 pa tudi s pegiliranim interferonom alfa in z adefovirjem. Rezultati. V obdobju 1194-2000 smo zdravili na različne načine petnajst bolnikov s kroničnim hepatitisom B (šest HBeAg pozitivnih) v treh do štirih enoletnih ciklusih s polletnimi prekinitvami, dvakrat z interferonom alfa, enkrat z interferonom alfa v kombinaciji z lamivudinom in enkrat z lamivudinom. Kljub dobri toleranci bolnikov na zdravila in spodbudnim rezultatom ob zaključkih posameznih ciklusov zdravljenja je sorazmerno hitro (3-6 mesecev) po prekinitvi zdravljenja pri večini prišlo do ponovnega poslabšanja z zvišanjem virusnega bremena in zvišanjem ALT v krvi, pri 3 bolnikih pa tudi do pojava odpornosti na lamivudin. Popoln odgovor na zdravljenje je do danes ohranilo 10 bolnikov (66,8`), 3 bolniki so v remisiji že pet let. Od l. 2003 dva bolnika, pri katerih je prišlo do ponovitve bolezni, zdravimo s pegiliranim interferonom a, bolnika z lamivudinsko odpornostjo pa z adefovirjem v kombinaciji z lamivudinom. (Izvleček skrajšan na 2000 znakov)"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-OEY6F73Y","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-OEY6F73Y"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-OEY6F73Y/b62581ce-a491-41fe-99a3-35faeaf94a2d/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-OEY6F73Y/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-OEY6F73Y"}}}}